These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The clinical and hemodynamic efficacy of telmisartan and enalapril in the treatment of arterial hypertension in patients with type 2 diabetes mellitus].
    Author: Tatarchenko IP, Pozdniakova NV, Mordovina AG, Morozova OI, Zaĭtseva AV.
    Journal: Ter Arkh; 2009; 81(12):11-5. PubMed ID: 20481040.
    Abstract:
    AIM: To study the effects of enalapril and telmisartan on hemodynamic parameters and diastolic function (DF) of the left ventricle (LV) in patients with type 2 diabetes mellitus (DM) concurrent with arterial hypertension (AH). SUBJECTS AND METHODS: The study included 64 patients (mean age 54.3 +/- 5.2 years) with type 2 DM. For the treatment of AH, Group 1 (n = 31) received enalapril and Group 2 (n = 33) took telmisartan (micardis). Their examination comprised 24-hour blood pressure (BP) monitoring, Holter ECG monitoring, and echocardiography. The fasting and postprandial levels of blood glucose and glycosylated hemoglobin were measured to evaluate the compensation for carbohydrate metabolism. RESULTS: In patients with type 2 DM and elevated BP, LV diastolic dysfunction was detectable in the absence of reduced contractility. LF DF, isovolumetric relaxation time, and the ratio of the peak blood flow velocity during early diastolic filling to that during atrial systole were found to correlate with HbA(1c), diastolic hypertension time index, and the diurnal duration of asymptomatic ST-segment depression. During enalapril therapy, the goal level of BP was achieved in systolic BP (SBP) in 77% of the patients and diastolic BP (DBP) in 64.5%, which was accompanied by reductions in the number of nondippers and night-pickers in 45.4% of cases with no changes in HbA(1c) and LV DF. CONCLUSION: In addition to effective SBP and DBP control with the normalization of their diurnal profiles in 87.5% of the patients with abnormal circadian rhythm, the 24-week course of telmisartan therapy ensures improvements in carbohydrate metabolism and LVDF.
    [Abstract] [Full Text] [Related] [New Search]